Halozyme Therapeutics, Inc.: Revision history

20 August 2022

• curprev 01:5401:54, 20 August 2022 95.149.241.133 talk 1,969 bytes +11 No edit summary undo

13 August 2022

• curprev 00:5500:55, 13 August 2022 109.180.50.163 talk 1,958 bytes +15 No edit summary undo

7 August 2022

• curprev 18:4118:41, 7 August 2022 >Paris 1,943 bytes +1,943 Created page with "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship p..."